Clinical Trial Update: Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions [Phase 1]

View source ↗

Summary

Phase 1 trial update on Terbinafine HCl 250 mg tablet formulations evaluated under non-fasting conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthy

Drugs mentioned

• Terbinafine HCl 250 mg Tablet (Terbinafine hydrochloride)

Snippet

Sponsor: Teva Pharmaceuticals USA | Conditions: Healthy | Phase 1 | Status: COMPLETED | Results posted: 2009-08-18